Information Provided By:
Fly News Breaks for April 26, 2016
CPRX
Apr 26, 2016 | 08:36 EDT
Piper Jaffray analyst Charles Duncan downgraded Catalyst Pharmaceuticals to Neutral with a reduced price target of $1 after the FDA required more studies for Firdapse.
News For CPRX From the Last 2 Days
There are no results for your query CPRX